SCHEMBL2239052

SCHEMBL2239052

CCOC(=O)C(CC(F)(F)F)(CC(F)(F)F)P(=O)(O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.36
CYP4A11 Q02928 2/20 0.36
MMP8 P22894 1/20 0.34
TSHR P16473 2/20 0.33
PKM P14618 2/20 0.33
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PTPN2 P17706 2/20 0.33
POLB P06746 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
THRB P10828 1/20 0.33
LMNA P02545 1/20 0.32
HSD17B10 Q99714 1/20 0.32
MAPT P10636 1/20 0.32
HIF1A Q16665 1/20 0.32
HTT P42858 2/20 0.32
LPAR1 Q92633 1/20 0.32
LPAR3 Q9UBY5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2234955 0.86 LPAR1 (0.33) ALDH1A1LPAR1LPAR3
SCHEMBL2238373 0.83 ALDH1A1 (0.40) TSHRALDH1A1LPAR1LPAR3
SCHEMBL171079 0.81 PTPN1 (0.38) ALDH1A1
SCHEMBL2239046 0.81 HTT (0.36) HTT
SCHEMBL16048 0.80 CYP4F2 (0.40) CYP4F2CYP4A11MMP8PKMALDH1A1
SCHEMBL18759662 0.80 CYP4F2 (0.40) CYP4F2CYP4A11MMP8PKMALDH1A1
SCHEMBL2239056 0.79 CYP4F2 (0.38) CYP4F2CYP4A11PKMALDH1A1KDM4E
SCHEMBL413276 0.79 CYP4F2 (0.39) CYP4F2CYP4A11MMP8PKMALDH1A1
SCHEMBL19278938 0.79 CYP4F2 (0.39) CYP4F2CYP4A11MMP8PKMALDH1A1
SCHEMBL2234947 0.78 FDPS (0.35) LMNAHSD17B10HTTLPAR1LPAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096905-A1 Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives GLAXO GROUP LIMITED (GB) 2008-04-24 US claimed
EP-1865959-A2 PROCESS FOR PREPARING PYRIDOÝ2,3-D¨PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDOÝ4,5-D¨PYRIMIDIN-2(1H)-ONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2007-12-19 EP claimed
US-20060258687-A1 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives GLAXO GROUP LIMITED (GB) 2006-11-16 US claimed
WO-2006104917-A2 PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2006-10-05 WO claimed
US-20260001903-A1 ASCAROSIDE DERIVATIVES AND METHODS OF USE CALIFORNIA INSTITUTE OF TECHNOLOGY 2026-01-01 US disclosed
US-12473323-B2 Ascaroside derivatives and methods of use CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2025-11-18 US disclosed
EP-4585265-A2 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2025-07-16 EP disclosed
US-12159967-B2 Nonaqueous electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-12-03 US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
US-12009482-B2 Nonaqueous electrolytic solution and electrical storage device including the same MITSUBISHI CHEMICAL CORPORATION (JP) 2024-06-11 US disclosed
US-20240128511-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2024-04-18 US disclosed
US-11942601-B2 Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same MITSUBISHI CHEMICAL CORPORATION (JP) 2024-03-26 US disclosed
WO-2006104915-A9 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES AND THEIR USE AS PHARMACEUTICALS GLAXO GROUP LTD (GB) 2008-01-03 WO disclosed
EP-1868611-A2 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-12-26 EP disclosed
WO-2007147103-A2 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-12-21 WO disclosed
EP-1865959-A2 PROCESS FOR PREPARING PYRIDOÝ2,3-D¨PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDOÝ4,5-D¨PYRIMIDIN-2(1H)-ONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2007-12-19 EP disclosed
US-20060258687-A1 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives GLAXO GROUP LIMITED (GB) 2006-11-16 US disclosed
US-20060235029-A1 Novel compounds GLAXO GROUP LIMITED (GB) 2006-10-19 US disclosed
WO-2006104915-A2 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES AND THEIR USE AS PHARMACEUTICALS GLAXO GROUP LIMITED (GB) 2006-10-05 WO disclosed
WO-2006104917-A2 PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258687-A1 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives CBR3, CBR1, CYP2S1 CYP4F2 18/4885CYP4A11 726/4885MMP8 4511/4885
US-20080096905-A1 Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives CYP2S1, CYP2F1, CBR3 CYP4F2 14/4885CYP4A11 612/4885MMP8 4666/4885
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 CYP4F2 444/4885CYP4A11 329/4885MMP8 301/4885
US-12473323-B2 Ascaroside derivatives and methods of use TLR4, TLR7, MYD88 CYP4F2 1807/4885CYP4A11 95/4885MMP8 268/4885
US-20260001903-A1 ASCAROSIDE DERIVATIVES AND METHODS OF USE HSD3B2, HSD3B1, NLRP3 CYP4F2 923/4885CYP4A11 66/4885MMP8 1901/4885
US-20060235029-A1 Novel compounds MAPKAPK2, CDC42BPB, MAPK8 CYP4F2 4246/4885CYP4A11 4032/4885MMP8 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.